Cybin Delivers Highest Dose Of Psilocybin Analog In Phase 2 For Major Depression - Cybin (AMEX:CYBN), Small Pharma (OTC:DMTTF)
Clinical-stage psychedelics biotech Cybin (NYSE: CYBN) has completed enrollment in its Phase 2 study of novel deuterated psilocybin analog CYB003 for the potential treatment of Major Depressive Disorder (MDD.)